The U.S. Food and Drug Administration added bemotrizinol to the over-the-counter sunscreen monograph on June 9, making it the first new active sunscreen ingredient permitted in the United States since the late 1990s. Manufacturers may begin incorporating the ingredient into consumer products starting August 9, 2026. The approval lands at the front edge of summer, and consumer health coverage from U.S. News & World Report, CNN, and Healthline continued through June 17 as dermatologists and advocacy organizations explained what the change means for everyday sun protection.
What Bemotrizinol Does Differently
Bemotrizinol — also marketed under the brand names PARSOL Shield and Tinosorb S — provides broad-spectrum protection against both ultraviolet A and ultraviolet B rays. That dual coverage is the feature that separates it from the existing U.S. sunscreen ingredient lineup.
The ingredient is highly photostable, meaning it does not break down when exposed to sustained sunlight. That characteristic addresses a long-standing weakness in the American sunscreen market. Avobenzone, currently the only non-mineral UVA filter approved for U.S. sunscreens, degrades under UV exposure and must be stabilized with additional chemicals to maintain its protective function. Bemotrizinol does not carry that limitation.
The FDA considers bemotrizinol generally recognized as safe and effective for use by adults and children six months of age and older, at concentrations up to 6%. Testing shows low levels of absorption through the skin, a property that contributed to the agency’s safety determination. DSM Nutritional Products LLC submitted the original monograph order request, and the FDA finalized the administrative order within seven months of issuing its proposed order in December 2025 — a pace enabled by the streamlined process established under the CARES Act.
A 25-Year Gap Between The U.S. And The Rest Of The World
Bemotrizinol has been used in sunscreen products across Europe, Australia, and Asia since 1999. The regulatory gap is structural: in most countries, sunscreens are classified as cosmetics, which allows new ingredients to reach shelves through a lighter approval pathway. In the United States, sunscreens are regulated as over-the-counter drugs, requiring more extensive safety and efficacy testing before an ingredient can be added to the monograph.
That classification difference kept American consumers locked into an ingredient set that had not changed in a quarter century while international markets adopted newer UV filters with broader protection profiles. The Environmental Working Group has noted that the protection gap is measurable: research cited by CNN indicates that most U.S. sunscreens currently provide only about one-quarter of the UVA protection their SPF labels suggest to consumers.
Dr. Mona Gohara, a board-certified dermatologist and associate clinical professor of dermatology at the Yale School of Medicine, told U.S. News & World Report that the approval reflects regulatory requirements rather than ingredient performance. Bemotrizinol’s efficacy was never in question internationally — it was the FDA’s classification framework that delayed its availability to American consumers.
The Formulation Advantage For Manufacturers
The ingredient’s approval opens a formulation pathway that U.S. sunscreen manufacturers have not previously had access to. Bemotrizinol can be combined with zinc oxide to produce broad-spectrum protection with a reduced white cast — the visible residue that mineral sunscreens leave on skin, particularly on darker skin tones. That formulation flexibility matters for compliance. Sunscreens that feel lighter, blend more cleanly, and avoid the white-cast problem tend to be applied more consistently, and consistent application is the single largest variable in real-world sun protection outcomes.
The Personal Care Products Council, the trade group representing sunscreen manufacturers, called the approval a significant advancement but pressed the FDA to move further, stating that continued efforts are needed to establish a more efficient process for approving additional active ingredients.
Products containing bemotrizinol may begin appearing on U.S. shelves as early as late 2026. The first wave is expected to arrive under the PARSOL Shield brand name, with broader availability following as manufacturers reformulate existing product lines. The competitive dynamics of the category will shift as brands race to market the ingredient as a differentiator — particularly among premium and dermatologist-recommended lines where UVA protection claims carry commercial weight.
Why The Timing Matters For Public Health
Skin cancer remains the most commonly diagnosed cancer in the United States. The Melanoma Research Foundation estimates more than 200,000 cases of melanoma in 2026, and the American Cancer Society attributes more than one death per hour to the disease. The American Academy of Dermatology reports that 57% of Americans use sunscreen regularly, while roughly one-third report at least one sunburn in the past year.
The gap between those numbers — majority usage but persistent burn rates — points to a product effectiveness problem alongside a behavior problem. Sunscreens that degrade under UV exposure, leave visible residue, or feel heavy on skin contribute to inconsistent application and reapplication. Bemotrizinol’s photostability and formulation versatility address the product side of that equation.
The FDA framed the approval inside the Make America Healthy Again strategy report, with HHS Secretary Robert F. Kennedy Jr. stating that the action will increase competition and consumer confidence in sunscreen products. Acting CDER Director Mike Davis called it an example of applying sound science to regulatory decisions under a modernized process.
What Consumers Should Watch For
Products will be labeled with bemotrizinol as an active ingredient on the Drug Facts panel, consistent with standard OTC sunscreen labeling. Consumers looking for the ingredient before branded products arrive can check for the PARSOL Shield name or bemotrizinol (BEMT) in active ingredient listings.
The full text of the FDA’s final administrative order, OTC000039, is published on the Federal Register and linked from the agency’s press announcement at fda.gov. The Environmental Working Group’s 2026 sunscreen guide, which evaluates products by UV filter performance and safety, is available at ewg.org.
